Work

P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.01.1084

Authors: B.C. Cho, Z. Piotrowska, X. Le, S.B. Goldberg, J. Goldman, A. De Langen, I. Okamoto, P. Smith, I. Mensi, J. Maidment, R. Hartmaier, M. Li, G. Doughton, G. Patel, J. Pease, P. Szekeres, J. Riess, H. Yu

Institutions: Severance Hospital, Yonsei Cancer Hospital, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Yale University, University of California, Los Angeles, The Netherlands Cancer Institute, Kyushu University, AstraZeneca (United Kingdom), AstraZeneca (United States), UC Davis Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3137656142

Cites:

Cited by: 3

Related to: 10